Connect your AI

Arcus Biosciences RCUS Financing Cash Flow

Financing Cash Flow at other companies

Bristol-Myers SquibbBMY

-$1.56B-57.1%

Merck & Co.MRK

-$2.98B+48.2%

Regeneron PharmaceuticalsREGN

-$802.2M+26.3%

AbbVieABBV

$919M+173%

ArriVent BioPharma, Inc.AVBP

$54.87M+712%

ImmunomeIMNM

-$135K-100%

Other financials

Income statement

Revenue$17.0M-39.3%

Operating income-$134.0M-9.8%

Net income-$128.0M-14.3%

EPS (diluted)-$1.02+10.5%

Balance sheet

Cash & equivalents$201.0M+4.7%

Total debt$113.0M+88.3%

Total equity$524.0M-1.3%

Total assets$997.0M-13.8%

Cash flow

Operating cash flow-$138.0M-4.5%

CapEx--100%

Free cash flow-$138.0M-3.8%

Valuation

Market cap$3.54B+226%

Enterprise value$3.46B+275%

P/S15×+7.3×

Profitability

Operating margin-168.6%-52.7pp

Net margin-156.4%-47.5pp

FCF margin-207.2%—

Returns & leverage

Return on equity-70%+8.4pp

Debt / equity0.2×+0.1×

Current ratio4×-1.3×

Where this comes from

Reported directly by Arcus Biosciences in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.

The official record: Arcus Biosciences’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Arcus Biosciences's financing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Arcus Biosciences's financing cash flow?: Arcus Biosciences (RCUS) reported financing cash flow of $3M in Q1 2026.
How has Arcus Biosciences's financing cash flow changed year-over-year?: Arcus Biosciences's financing cash flow decreased by 97.9% year-over-year, from $142M to $3M.
What is the long-term trend for Arcus Biosciences's financing cash flow?: Over 4 years (2021 to 2025), Arcus Biosciences's financing cash flow has grown at a 19.8% compound annual growth rate (CAGR), from $237M to $488M.
What does financing cash flow mean?: Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.